FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally ...
SAN FRANCISCO, Jan. 27, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FibroGen) today announced early results from a Phase 2, randomized, open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and nab-paclitaxel …